SG11201901999XA - Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making - Google Patents
Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of makingInfo
- Publication number
- SG11201901999XA SG11201901999XA SG11201901999XA SG11201901999XA SG11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- loxl2
- methods
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 | |
| PCT/US2017/050332 WO2018048943A1 (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901999XA true SG11201901999XA (en) | 2019-04-29 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901999XA SG11201901999XA (en) | 2016-09-07 | 2017-09-06 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (ko) |
| EP (1) | EP3510023B1 (ko) |
| JP (1) | JP7079772B2 (ko) |
| KR (1) | KR102587178B1 (ko) |
| CN (1) | CN109983006B (ko) |
| AU (1) | AU2017324445A1 (ko) |
| BR (1) | BR112019004517A2 (ko) |
| CA (1) | CA3036064A1 (ko) |
| EA (1) | EA201990621A1 (ko) |
| IL (1) | IL265192A (ko) |
| MA (1) | MA46204A (ko) |
| MX (1) | MX2019002615A (ko) |
| SG (1) | SG11201901999XA (ko) |
| WO (1) | WO2018048943A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2872553T3 (es) * | 2015-03-06 | 2021-11-02 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo-2 y usos de los mismos |
| SG11201707246YA (en) | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP2019508400A (ja) * | 2016-02-09 | 2019-03-28 | ファーマケア，インク． | キノリノンリシルオキシダーゼ様２阻害剤とその使用 |
| MX2019002615A (es) | 2016-09-07 | 2019-10-15 | Pharmakea Inc | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
| MX2019002612A (es) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Usos de un inhibidor de lisil-oxidasa tipo 2. |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) * | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| IL150632A0 (en) | 2000-01-18 | 2003-02-12 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1816544B (zh) | 2003-05-19 | 2011-06-08 | Irm有限责任公司 | 免疫抑制剂化合物和组合物 |
| WO2005082370A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| WO2005090286A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| ATE545413T1 (de) | 2004-03-15 | 2012-03-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| MXPA06012333A (es) | 2004-04-30 | 2007-01-17 | Takeda Pharmaceutical | Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13. |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| CA2580034A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| BRPI0514793A (pt) | 2004-09-10 | 2008-06-24 | Pfizer Prod Inc | uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| US7759493B2 (en) | 2005-01-31 | 2010-07-20 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| CA2618586A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| EP1978966A4 (en) | 2006-01-23 | 2010-11-10 | Amira Pharmaceuticals Inc | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| WO2008020799A1 (en) | 2006-08-18 | 2008-02-21 | Astrazeneca Ab | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| CN101835490A (zh) | 2007-08-02 | 2010-09-15 | 阿雷斯托生物科学股份有限公司 | Lox和loxl2抑制剂及其应用 |
| JP2013500974A (ja) | 2009-07-28 | 2013-01-10 | アナコール ファーマシューティカルズ，インコーポレイテッド | 三置換ホウ素含有分子 |
| RU2012110587A (ru) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Терапевтические способы и композиции |
| RU2549684C2 (ru) | 2010-02-04 | 2015-04-27 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| EP2542089B1 (en) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| BR112014009531A8 (pt) | 2011-10-20 | 2018-01-16 | Glaxosmithkline Llc | aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína |
| CN104364235B (zh) | 2012-04-25 | 2017-07-04 | 拉夸里亚创药株式会社 | 作为ttx‑s阻断剂的酰胺衍生物 |
| EA201590630A1 (ru) * | 2012-10-30 | 2015-10-30 | Джилид Сайэнс, Инк. | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) |
| EP2937335A4 (en) | 2012-12-18 | 2016-09-14 | Ea Pharma Co Ltd | HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH |
| JP2018522812A (ja) | 2014-08-05 | 2018-08-16 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | カスパーゼ−６のモジュレーター |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| PE20180177A1 (es) | 2015-02-15 | 2018-01-22 | Hoffmann La Roche | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 |
| SG11201707246YA (en) * | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| ES2872553T3 (es) | 2015-03-06 | 2021-11-02 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo-2 y usos de los mismos |
| MX2019002615A (es) * | 2016-09-07 | 2019-10-15 | Pharmakea Inc | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
| MX2019002612A (es) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Usos de un inhibidor de lisil-oxidasa tipo 2. |
-
2017
- 2017-09-06 MX MX2019002615A patent/MX2019002615A/es unknown
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 CA CA3036064A patent/CA3036064A1/en active Pending
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/en active Active
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/en unknown
- 2017-09-06 BR BR112019004517A patent/BR112019004517A2/pt unknown
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active IP Right Grant
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA46204A (fr) | 2021-03-17 |
| AU2017324445A1 (en) | 2019-04-11 |
| CA3036064A1 (en) | 2018-03-15 |
| WO2018048943A1 (en) | 2018-03-15 |
| JP2019532919A (ja) | 2019-11-14 |
| JP7079772B2 (ja) | 2022-06-02 |
| BR112019004517A2 (pt) | 2019-08-13 |
| EA201990621A1 (ru) | 2019-09-30 |
| KR20190052040A (ko) | 2019-05-15 |
| US20200361901A1 (en) | 2020-11-19 |
| EP3510023B1 (en) | 2024-06-19 |
| CN109983006A (zh) | 2019-07-05 |
| EP3510023A4 (en) | 2020-03-18 |
| US11459309B2 (en) | 2022-10-04 |
| IL265192A (en) | 2019-05-30 |
| EP3510023A1 (en) | 2019-07-17 |
| US20190202805A1 (en) | 2019-07-04 |
| CN109983006B (zh) | 2022-02-25 |
| MX2019002615A (es) | 2019-10-15 |
| KR102587178B1 (ko) | 2023-10-06 |
| US10774069B2 (en) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901999XA (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201408140QA (en) | Crystalline forms of an androgen receptor modulator | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201906222WA (en) | Jak1 selective inhibitors |